1. 2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma. (18th September 2019) Authors: Coleman, R; Oza, AM; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, JI; Clamp, AR; Scambia, G; Leary, A; Holloway, RW; Amenedo Gancedo, M; Fong, PC; Goh, JC; O'Malley, DM; Goble, S; Cameron, T; Bedel, J; Ledermann, JA Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. (1st November 2019) Authors: Colombo, N; Oza, AM; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Weberpals, JI; Clamp, AR; Scambia, G; Leary, A; Holloway, RW; Amenedo Gancedo, M; Fong, PC; Goh, JC; O'Malley, DM; Armstrong, DK; Banerjee, S; García-Donas, J; Swisher, EM; Meunier, J Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3. (1st November 2019) Authors: Clamp, AR; Oza, AM; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, JI; Scambia, G; Leary, A; Holloway, RW; Amenedo Gancedo, M; Fong, PC; Goh, JC; O'Malley, DM; Armstrong, DK; Banerjee, S; García-Donas, J; Swisher, EM; Cameron, T Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations. (13th November 2020) Authors: Weberpals, J; Oza, A; Lorusso, D; Scambia, G; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Clamp, AR; Leary, A; Holloway, RW; Amenedo Gancedo, M; Fong, PC; Goh, JC; O'Malley, DM; Armstrong, DK; Banerjee, S; García-Donas, J; Swisher, EM; Cameron, T Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗